TubeRank
LCIDBearhit
Lucid CityLucid City

Target Price(split-adjusted)

$22.10

Said $2.21· today's shares after the 1-for-10 reverse split (Sep 2025)

I do feel in the early part of the week you will see it briefly below this 221@ 11:26 · open at this moment on YouTube ↗

Thesis at the time

Mixed

Lucid has dropped 14% in 5 days on extraordinary volume (259M and 262M shares in consecutive days) with no news, suggesting dilution via the active S-3 shelf offering or a major institution selling. The speaker sees a near-term dip below $2.21 possible but expects a recovery and calls current prices a buying opportunity for long-term believers. A June 7th studio event could be the trigger for a catalyst.

Key arguments

  • Extraordinary volume (259M+ shares/day) without news strongly suggests dilution or major institution selling
  • Active S-3 shelf offering from 2023 allows dilution without immediate disclosure
  • Breaking below 50-day MA historically results in a ~30% pullback, implying ~$2 support
  • June 7th Lucid Studio event could trigger Gravity test drive announcements
  • Negative delta of -457K shares shows options market mechanics are adding selling pressure

Counter-arguments acknowledged

  • Good data points or China deal this week could trigger recovery to S1–S2 range
  • Stock is excessively oversold — strong buyers could emerge at current levels

The call

Date said
Jun 1, 2025
Deadline
Jun 4, 2025
Price at prediction
$22
Confidence
medium
Specificity
specific

How it resolved

Status
hit
Resolution price
$22
Return
0.0%
Notes
Target ≤$22.1 reached on 2025-06-02. Price: $22.00. Return: 0.0%.
Why this resolved this way(resolution audit)
Reference price
$22 (anchored at quote date)
Target used
$22.10(split-adjusted from $2.21)
Deadline source
Explicit (extracted from quote)
Effective: Jun 4, 2025
Age at resolution
0.0 months(from publish date)
Resolution snapshot
$22 on Jun 2, 2025

Rule that fired

Target ≤$22.1 reached on 2025-06-02. Price: $22.00. Return: 0.0%.

Full rules: docs/resolution-spec.md.